AMA Statement on updated COVID-19 boosters

Translate to Spanish or other 102 languages!

“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses."  Image for illustration purposes
“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses.” Image for illustration purposes

Mega Doctor News

- Advertisement -
Sandra Adamson Fryhofer, M.D.
Image Source: ama-assn.org

The following statement is attributable to:
Sandra Adamson Fryhofer, M.D.
Board Chair, American Medical Association

“Given that the BA.5 Omicron subvariant is responsible for the majority of COVID-19 infections currently circulating throughout the U.S., we welcome today’s recommendations by the Advisory Committee on Immunization Practices (ACIP) supporting a bivalent booster dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines—targeting the BA.4/BA.5 Omicron subvariants as well as the original variant. ACIP’s recommendations, following the U.S. Food and Drug Administration’s (FDA) authorization on Wednesday, will allow individuals 12 years and older to receive a booster dose of Pfizer’s bivalent vaccine and anyone 18 years and older to receive a booster dose of Moderna’s bivalent vaccine at least two months after completing their primary vaccine series or their most recent booster. The bivalent booster recommendation replaces previous booster recommendations with a monovalent booster dose for people ages 12 years and older.

“With COVID-19 infections continuing to impact the U.S. population and an increase in infections expected this fall and winter, data shows that the updated bivalent vaccines will increase immune response and help provide protection against severe COVID-19 outcomes including hospitalization and death. Vaccine effectiveness against SARS-CoV-2 infection wanes over time and vaccine booster doses have been shown to increase protection. With the highly transmissible Omicron variant continuing to evolve, broad update of a bivalent booster dose will help provide an additional layer of protection and could prevent more than 100,000 hospitalizations compared to a later roll-out.”

- Advertisement -

“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses, to protect themselves and their loved ones from severe complications, hospitalization, and death. Anyone with questions about the vaccines should speak with their physician and review trusted resources, including getvaccineanswers.org.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

AMA Advises Patients to Check with Doctors on Web Advice

The internet offers no shortage of health advice. But with misleading medical claims spread across social media, search engines, and AI platforms, finding trustworthy answers can be a challenge. 

FDA Authorizes Focused Ultrasound Treatment for Varicose Veins

Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
- Advertisement -